Wasps Create a Buzz with Antibiotics
Scientists of the Max Planck Institute for Chemical Ecology in Jena and researchers at the University of Regensburg and the Jena Leibniz Institute for Natural Product Research discovered that bacteria of the genus Streptomyces produce a cocktail of nine different antibiotics, thereby fending off invading pathogens.
Many insects spend a part of their life underground and are exposed to the risk of fungal or bacterial infections. This is also the case for many digger wasp species that construct underground nests. Unlike bees that use pollen and nectar as food to nurture their larvae, digger wasps hunt insects to feed their offspring. Because of the warm and humid conditions as well as the large amounts of organic material in their subterranean nest, both their food supply and their larvae are endangered by pathogens. Mold and bacterial infection are a major threat and can cause larval death in many cases.
Antibiotics on the surface of the cocoon, produced by symbionts, guarantee protection against microbial pests during such a protracted developmental stage.
An analysis of the substances involved not only contributes to the understanding of the evolution of such symbioses, but could also lead to the discovery of interesting new drug candidates for human medicine.
With their work the researchers are breaking new ground: "Astonishingly, little is known about the ecological importance of antibiotics in their natural environment. Supported by mass spectrometric imaging we are now able to better understand the natural role of antibiotic substances in the environment," says Aleš Svatoš, leader of the mass spectrometry research group.
"We suppose that protective symbioses like the ones between beewolves and Streptomyces bacteria are much more common in the animal kingdom than previously assumed," says Martin Kaltenpoth. "An analysis of the substances involved not only contributes to the understanding of the evolution of such symbioses, but could also lead to the discovery of interesting new drug candidates for human medicine."
The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.
